menu
    • menu
    [{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Scientific Services \/ Ethypharm"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fentanyl","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"MALTA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Adalvo"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kirin \/ Grunenthal"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal Meds","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Grunenthal Meds","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Grunenthal Meds \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal Meds \/ Grunenthal"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nutriband \/ Not Applicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Aveva Drug Delivery Sytems, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aveva Drug Delivery Sytems, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fentanyl

    Menu

    Fentanyl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aveva Launches Generic Fentanyl TDS, Third Complex Transdermal Drug in 15 Months

                            Details : Fentanyl TDS, a prescriptional 3-day transdermal patch is launched for managing moderate to severe chronic pain which is generic equivalent to Duragesic.

                            Product Name : Duragesic-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nutriband and Kindeva to Co-Develop Aversa Fentanyl Abuse-Deterrent Patch

                            Details : Nutriband is partnering with Kindeva to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.

                            Product Name : Aversa Fentanyl

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nutriband Provides Product Development Update for its Lead Product Aversa Fentanyl

                            Details : Aversa fentanyl abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, & accidental exposure of drugs.

                            Product Name : Aversa Fentanyl

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 20, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $8.4 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Nutriband Raises $8.4M for Aversa® Fentanyl Patch FDA Submission

                            Details : Net proceeds will fund the development of AVERSA Fentanyl, a potential first abuse-deterrent opioid patch to reduce misuse and accidental exposure risks with transdermal fentanyl.

                            Product Name : Aversa Fentanyl

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $8.4 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $8.4 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Nutriband Inc. Announces $8.4M Private Placement

                            Details : The primary use of proceeds will be for completing the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval.

                            Product Name : Aversa Fentanyl

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 19, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $8.4 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nutriband Provides Overview for AVERSA(R) Fentanyl Transdermal Patch

                            Details : Aversa (fentanyl) utilizes abuse-deterrent transdermal technology with aversive agents to prevent drug abuse, diversion, and accidental exposure.

                            Product Name : Aversa Fentanyl

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kindeva Drug Delivery

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Kindeva Drug Delivery

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Nutriband

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nutriband Signs Agreement with Kindeva for Abuse Deterrent Fentanyl Patch

                            Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.

                            Product Name : Aversa Fentanyl

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 05, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Nutriband

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Grunenthal Meds

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed

                            Grunenthal Meds

                            United Kingdom arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Grunenthal

                            Deal Size : $83.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration

                            Details : The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteo...

                            Product Name : Abstral

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 02, 2023

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Grunenthal

                            Deal Size : $83.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towa...

                            Details : The net proceeds will be used to fund the development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.

                            Product Name : Aversa

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 14, 2023

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Nutriband

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Sca...

                            Details : AVERSA™ (fentanyl) combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch system.

                            Product Name : Aversa

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2023

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Kindeva Drug Delivery

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth